This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 Dec 2018


The global pharmaceutical industries will continuously grow in developing biologic drugs. Global pharmaceutical companies will allocate more resources to develop innovative drugs, cutting-edge med-tech, and precise medical treatment. In addition, most pharmaceutical companies will increase their R&D efficiency and adopting to advancements in industrial automation.

Due to this the South Asian and African pharmaceutical industry is witnessing a surge in tax reforms, turbulent equity markets, and the strengthening global economy. The growth of the pharmaceutical industry is boosted by healthcare digitalization and democratization, creating an explosion in patient data, and the emergence of value-based reimbursement models. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics—enabled by digital connectivity—is driving regulatory and commercial changes in many exciting ways for the industry.   We also believe, small- to medium-sized merger and acquisition activities will increase. Post M&A and integration will differentiate the top-tier pharmaceutical companies from each other. I believe opportunity and risk co-exist. In Asia markets, we are optimistic due to the fragmented population, demand for qualified healthcare services, growing automation requirements and the growth of health insurance.   Regarding the India market, Indian pharmaceutical companies have a competitive advantage in generics. They will increase their competitiveness on the global pharmaceutical markets and create pressure for top-tier companies, particularly from their cost structure. In addition, as Indian companies invest more and more in production facilities throughout Africa, understanding more about these North-South and South-South partnerships and their associated knowledge and technology transfer policies becomes relevant. India’s approach to patent recognition is seen as a model that should be implemented in other developing countries.

Despite being an old concept, automation and the extent of its adoption is at its highest peak in the industry. Therefore, pharmaceutical organizations need a better understanding of its benefits and ensure they have a stringent automation strategy in place to guarantee they partner with the best technology provider that can deliver business efficiency without compromising security   Gandhi Automations Pvt Ltd, as a family-focused multinational company rooted in India, adheres to its globalization strategy and believes there are still huge opportunities in developing countries, for instance, India, Southeast Asia and Africa. India has grown tremendously in the past four decades; our management team believes that we can provide valuable experience contribute to another growth miracle in those markets. Current investment areas in these markets include industrial automation, warehousing, pharmaceuticals, consumption upgrades, logistics, among others.

Mentioned Companies
Gandhi Automations Pvt Ltd
View company profile